Pulmonary adverse events following immune checkpoint inhibit... : Current Opinion in
Pulmonary Medicine Pulmonary adverse events following immune checkpoint inhibitors …

Background Imbalanced body composition is mechanistically connected to dysregulated
immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment …

Importance Immune-related adverse events (irAEs) secondary to immune checkpoint
inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell …

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung
cancer (NSCLC) accounts for approximately 80% of all lung cancers, and most NSCLC is …

Safe and effective prophylactic vaccines are urgently needed to contain the coronavirus
disease 2019 (COVID-19) pandemic. However, several vaccination-related adverse effects …

Background: Nivolumab has been approved in China as second-line treatment for advanced
non-small-cell lung cancer (NSCLC) via weight-based infusion, based on the CheckMate …

Background PD-1 is an immune checkpoint on T cells, and interventions to block this
receptor result in T cell activation and enhanced immune response to tumors and …

Background There is limited evidence regarding immune-related adverse events (irAEs) in
Asian cancer patients treated with antibodies directed against programmed cell death-1 (PD …

The emergence of immune checkpoint inhibitors (ICIs) has heralded a transformative era in
the therapeutic landscape of non‐small cell lung cancer (NSCLC). While ICIs have …

Simple Summary Despite the great achievements of cancer immunotherapy in a variety of
tumors, tumor heterogeneity and drug resistance still plague patients and clinical …